Exactly! The old Phase III was truncated at 168 hours so the benefit seen after 168 hours was not factored in. The redesign negates that as well as pain scores and subjectivity. The way they are obtaining the data is the clearest way possible to show the treatment affect.
I hope so. He has hit every target he has made for this company. It would be a shame if he didn't succeed.
I'd rather they say "we are confident that EPIC is positive and we have potential suitors who are offering to acquire Mast in the billions of dollars". I've been invested in this company for 6 years so I am anxious to see how it pans out.
As discussed below under “Management Outlook,” we do not believe our cash, cash equivalents and investment securities as of March 31, 2016 will be sufficient to meet our currently planned operations for the next 12 months, and these circumstances raise substantial doubt about our ability to continue as a going concern. If we have positive results from our Phase 3 clinical study of vepoloxamer in sickle cell disease, known as the EPIC study, but we are unable to raise sufficient additional capital before the fourth quarter of 2016, we plan to reduce the scope of our operations, including by delaying or discontinuing investment in development and commercialization efforts for vepoloxamer in sickle cell disease and heart failure. In the event of negative results from the EPIC study and prepayment to our lender on July 31, 2016 of $10 million of the principal balance under our debt facility, as would be required by its terms, we also plan to immediately and significantly reduce the scope of our operations. - It just doesn't paint a nice picture. I own stock but its just a little unsettling that there main thing was to commercialize it themselves, however even if the results are positive they have no money to do so.
Reading the 10-Q doesn't make me feel good. They do not have enough cash for the remaining 9 months. They will need raise additional capital through debt, equity or other agreements. If EPIC doesn't pass, the company will fold.